Literature DB >> 9044234

Applicability of VO2max criteria: discontinuous versus continuous protocols.

G E Duncan1, E T Howley, B N Johnson.   

Abstract

This study compared the classic discontinuous Taylor et al. (1955) protocol to a continuous version of the same protocol to evaluate maximal physiological responses, and the quantitative values and incidence of achievement of the various maximal oxygen uptake (VO2max) criteria in 10 males (24.1 +/- 2.5 yr). Criteria were a plateau in VO2 (change < 2.1 ml.kg-1.min-1), HR = age adjusted maximal, PER > or = 1.15, and lactate > 8 mmol.l-1. Values for VO2max (56.8 +/- 4.7 vs 55.8 +/- 4.2 ml.kg-1.min-1), ventilation (150.7 +/- 16 vs 149.5 +/- 17.5 l.min-1 BTPS), and HR (186.3 +/- 7.7 beats.min-1 vs 191.7 +/- 6.7 beats.min-1) were similar (P < 0.05) between the discontinuous protocol (DT) and the continuous protocol (CT), respectively. Values for RER (1.28 +/- 0.05 vs 1.22 +/- 0.05) and lactate (14.3 +/- 2.7 vs 11.9 +/- 2.7 mmol.l-1) were greater (P < 0.05) on the DT than the CT. Criteria achievement were the following: 40% (CT) and 10% (DT) for HR; 50% (CT) and 60% (DT) for a VO2 plateau; and, 90% (CT) and 100% (DT) for RER and lactate. It is concluded that a VO2 plateau is not a prerequisite for defining VO2max and is of limited use as the primary objective criterion for evaluating the quality of a graded exercise test. Therefore, the achievement of secondary objective criteria, specifically RER and lactate in combination, increases the likelihood that the highest VO2 value achieved is VO2max.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9044234     DOI: 10.1097/00005768-199702000-00017

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  40 in total

Review 1.  Neural control of force output during maximal and submaximal exercise.

Authors:  A St Clair Gibson; M L Lambert; T D Noakes
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

2.  Low frequency of the "plateau phenomenon" during maximal exercise in elite British athletes.

Authors:  M Doherty; L Nobbs; T D Noakes
Journal:  Eur J Appl Physiol       Date:  2003-05-21       Impact factor: 3.078

3.  Effects of aerobic endurance training status and specificity on oxygen uptake kinetics during maximal exercise.

Authors:  Fabrizio Caputo; Benedito Sérgio Denadai
Journal:  Eur J Appl Physiol       Date:  2004-07-10       Impact factor: 3.078

4.  Validity of heart rate as an indicator of aerobic demand during soccer activities in amateur soccer players.

Authors:  Fabio Esposito; Franco M Impellizzeri; Vittoria Margonato; Rosalba Vanni; Giuliano Pizzini; Arsenio Veicsteinas
Journal:  Eur J Appl Physiol       Date:  2004-07-22       Impact factor: 3.078

5.  Relationship between stress hormones and testosterone with prolonged endurance exercise.

Authors:  W Daly; C A Seegers; D A Rubin; J D Dobridge; A C Hackney
Journal:  Eur J Appl Physiol       Date:  2004-11-20       Impact factor: 3.078

6.  Cycling time trial performance during different phases of the menstrual cycle.

Authors:  Tanja Oosthuyse; Andrew N Bosch; Susan Jackson
Journal:  Eur J Appl Physiol       Date:  2005-03-19       Impact factor: 3.078

7.  Peak oxygen uptake. Myth and truth about an internationally accepted reference value.

Authors:  T Meyer; J Scharhag; W Kindermann
Journal:  Z Kardiol       Date:  2005-04

8.  Correlations between physiological variables and performance in high level cross country off road cyclists.

Authors:  F M Impellizzeri; S M Marcora; E Rampinini; P Mognoni; A Sassi
Journal:  Br J Sports Med       Date:  2005-10       Impact factor: 13.800

9.  Elucidating determinants of the plateau in oxygen consumption at VO2max.

Authors:  T A Astorino; J Willey; J Kinnahan; S M Larsson; H Welch; L C Dalleck
Journal:  Br J Sports Med       Date:  2005-09       Impact factor: 13.800

Review 10.  Exercise programmes for patients with chronic heart failure.

Authors:  Tim Meyer; Michael Kindermann; Wilfried Kindermann
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.